We suppose that breast cancer patients with higher tumor Cav-1 expression may transport more nab-paclitaxel into the breast cancer cells through transcytosis and show better efficacy with higher tumor intracellular concentrations of nab-paclitaxel. The gene discussed is CAV1; the disease is breast cancer.